NCT04200079 (KCOCO) is a clinical trial in COPD, sponsored by Dr. Juan Pablo de Torres Tajes.

Who is sponsoring NCT04200079?

NCT04200079 is sponsored by Dr. Juan Pablo de Torres Tajes.

What condition does NCT04200079 study?

NCT04200079 studies COPD, Emphysema.

Is NCT04200079 still recruiting?

NCT04200079 is currently recruiting now. Last updated 14 September 2021.

Last reviewed 2021-09-14 · How we verify

NCT04200079: KCOCO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Kingston Chronic Obstructive Pulmonary Disease (COPD) Multidimensional Long Term Follow up Cohort

Recruiting now Last updated 14 September 2021

What this trial tests

trial in COPD in 400 participants. Currently enrolling.

Timeline

14 January 2020

Primary endpoint
31 December 2030

31 December 2030

Quick facts

Lead sponsor	Dr. Juan Pablo de Torres Tajes
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	400
Start date	14 January 2020
Primary completion	31 December 2030
Estimated completion	31 December 2030
Sites	1 location across Canada

Conditions studied

COPD — all drugs for COPD →
Emphysema — all drugs for Emphysema →

Sponsor

Dr. Juan Pablo de Torres Tajes

Who can join

Adults 40 to 85, any sex, with COPD or Emphysema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: Chronic Obstructive Pulmonary (COPD) patients are the paradigm of the chronic complex patient. Their follow up can sometimes be difficult and challenging (1). There are patients with recurrent exacerbations that put an enormous burden on health care resources (2). They also have multiple comorbidities (3) that can sometimes make their management difficult. In an attempt to coordinate all these efforts KGH, HDH and Providence Care have numerous essential resources to take care of COPD patients like the nurse navigators, nurse practitioners and the pulmonary rehabilitation program. These programs provide an excellent support to the clinical activity of Respirologists and other health care providers. Rationale: The main rationale for the development of the Kingston COPD cohort is to translate that highly demanding clinical activity in a teaching and research oriented activity that could be used by clinicians, medical students, residents and fellows. Having a guideline complained established protocol in COPD patients that are usually follow at KGH and HDH could help in not only in unified the way COPD patients are seeing (preserving the importance of the personalized approach) but most importantly established a multidimensional (clinical, physiological, radiological, laboratory) database. This could help know not only the results of our clinical activity but also have a long term (\>5yrs) database for clinical research projects in collaboration with national and international research groups. Therefore this proposal is important because it will help translate our busy daily clinical work in a highly productive teaching and research activity.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for COPD

Currently open trials in the same condition.

NCT07344649 — Turkish Validation of the Nijmegen Questionnaire in COPD · recruiting
NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
NCT07460154 — Structured Review: To Optimise Management and Prevent Harm in COPD · NA · recruiting
NCT07462221 — Effect of Telenursing on Oral Health · NA · recruiting
NCT07051707 — Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04200079 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dr. Juan Pablo de Torres Tajes
Last refreshed: 14 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04200079.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing